Oritavancin for the Treatment of Staphylococcus aureus Bacteremia—A Retrospective Single-arm Cohort Study

• by H Jordan, K Kozierowski, R Pickles, J S Davis

• June 12, 2025

Is “Against Medical Advice” Still Defensible?

A Viewpoint calls for more dignifying, harm-reduction–oriented hospital discharges for patients with OUD.

• by Kerri Miller

• April 14, 2026

• 3 min

Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis

• by Thomas P. Lodise, Nicholas A. Turner, Toshimitsu Hamasaki, Nick Fishbane, Varduhi Ghazaryan, Alison Wall, Lizhao Ge, Qihang Wu, Lijuan Zeng, Todd Riccobene, Rinal Patel, Smitha Zaharoff, Urania Rappo, Scott Evans, Vance G. Fowler, Henry F. Chambers, Thomas L. Holland, Antibacterial Resistance Leadership Group, Robin Patel, Heather Cross, Anthony Harris, Melinda Pettigrew, David van Duin, Helen Boucher, Clayton Huntley, Erica Raterman, Tamika Samuel, Kyung Moon, Kim Hanson, Yohei Doi, Tom Lodise, Ritu Banerjee, Sara Cosgrove, David Paterson, Ebbing Lautenbach, Maureen Mehigan, Sarah Doernberg, Sam Perdue

• April 18, 2026

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

• by Kathryn Wighton

• January 27, 2026

• 3 min